Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 7/20 | 0.42 |
| ▸ | CDK8 | P49336 | 7/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.37 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.37 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831275 | 1.00 | EGFR (0.43) | EGFRMMP1MMP2MMP9CCNC | |
| SCHEMBL4826902 | 0.88 | PTGDR2 (0.40) | EGFRMMP1MMP2MMP9CCNC | |
| SCHEMBL4833258 | 0.88 | CCNC (0.44) | EGFRMMP1MMP2MMP9CCNC | |
| SCHEMBL4833243 | 0.88 | CCNC (0.44) | EGFRMMP1MMP2MMP9CCNC | |
| SCHEMBL6429798 | 0.87 | MMP1 (0.46) | EGFRMMP1MMP2MMP9CCNC | |
| SCHEMBL4831171 | 0.85 | CCNC (0.44) | EGFRMMP1MMP2MMP9CCNC | |
| SCHEMBL4834355 | 0.85 | CCNC (0.44) | EGFRMMP1MMP2MMP9CCNC | |
| SCHEMBL4831155 | 0.85 | CCNC (0.44) | EGFRMMP1MMP2MMP9CCNC | |
| SCHEMBL4826913 | 0.85 | CCNC (0.39) | EGFRMMP1MMP2MMP9CCNC | |
| SCHEMBL4826898 | 0.85 | CCNC (0.39) | EGFRMMP1MMP2MMP9CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | EGFR 802/4885MMP1 4721/4885MMP2 4741/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | EGFR 802/4885MMP1 4721/4885MMP2 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.